-
The Adenosine Axis: How CD39 and CD73 Switch Immunity Off(Post)
The most abundant immunosuppressive molecule in a solid tumour is not a protein. It is adenosine — a metabolite, produced from ATP in two enzymatic steps, at concentrations orders of magnitude above
Complement: The Brake Matters More Than the Trigger(Post)Complement is firing on your own cells right now. Not in response to anything — C3 hydrolyses spontaneously in plasma at a low, constant rate, and every hydrolysed molecule is a potential convertase
Cleaved Caspase-3 and Apoptosis(Post)Cell Death · BiomarkersCleaved Caspase-3: Activation, Function and Detection in ApoptosisCaspase-3 sits at the point where apoptotic signalling becomes irreversible. It is made as an inactive proenzym
Utomilumab: Advancing Immuno-Oncology Research(Post)Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.
CD25 Marker(Post)CD25, a key molecule in immune regulation, is integral to the function of activated lymphocytes and regulatory T cells. It's central in mediating immune responses, with implications in autoimmune
The Rise of Alpha-Emitting Radiopharmaceuticals: A New Era in Targeted Cancer Therapy(Post)Imagine a microscopic sniper, capable of delivering a lethal blow to a single cancer cell while leaving its healthy neighbors virtually untouched. This is the promise of targeted alpha therapy, a rev
Antibody Conjugation: Techniques and Applications(Post)Antibody conjugation is a pivotal technique in biomedical research and diagnostic applications. This process involves the covalent attachment of a molecule, such as a drug, toxin, enzym
Antigen Processing and Presentation: MHC-I, MHC-II, Cross-Priming(Post)Every T-cell response begins with a protein being taken apart. Before a CD8 or CD4 T cell can see anything, an antigen has to be degraded into peptides of the right length, delivered to the right com
Allorecognition Pathway: Transplant Rejection, DSA and GvHD(Post)Transplant rejection is the fastest, most violent adaptive immune response a body can mount — and it is a response to a molecule rather than to a pathogen. Somewhere between one and ten per cent of a
HERV-K group of endogenous retroviruses and cancer(Post)In 2006, upon completion of the Human Genome Project, it was discovered that nearly 8% of the human genome is made up of viral DNA. These viral remnants are composed of ancient germl
Do Not Eat Me Is Not a Switch(Post)Phagocytosis is a subtraction, not a switch. A macrophage engulfs when its activating signals exceed its inhibitory ones, and every awkward result in the myeloid checkpoint field falls out of that on
Freezing Stimulated T Cells: A Detailed Guide(Post)Cryopreservation of stimulated T cells is a common technique in immunology research, allowing for long-term storage while maintaining their functional viability. Stimulated T cells—especi
The Interferonopathies and the Self-DNA Problem(Page) Positive Control vs Negative Control(Post)T cell activation is a crucial process in the immune response, playing a pivotal role in how the body responds to pathogens and maintains immune homeostasis. This intricate process involves severa
Ferroptosis Assays(Page)Ferroptosis Assay Kits | Lipid Peroxidation, Iron & Glutathione | Assay Genie
Mycoplasma Detection Kit Troubleshooting: The Importance of Cell Confluence(Post)Quick answer A researcher's samples read negative at the standard 1-hour incubation on the MycoGenie Rapid Mycoplasma Detection Kit (MORV0011), but many turned positive after 2 hours.
TNFR2: Taming Regulatory T Cells to Enhance Anti-Tumor Immunity(Post)In recent years, cancer immunotherapy has become a powerful tool for treating various malignancies. One promising approach involves targeting the tumor microenvironment, particularly regu
Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat
Top 10 Therapeutics(Page) Monalizumab: A Breakthrough in Cancer Immunotherapy Targeting NKG2A(Post)Quick Facts About MonalizumabWhat is Monalizumab?Monalizumab is a first-in-class immune checkpoint inhibitor targeting NKG2A, developed to enhance anti-tumor immune response by blocking